Clinical Trial Update: CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL） [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CART-19, a CD19-targeted CAR-T cell therapy, for relapsed or refractory acute lymphoblastic leukemia; the status is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CART-19 (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Leukemia, Lymphocytic, Acute | Phase 1, Phase 2 | Status: UNKNOWN